Identification
- Summary
Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.
- Brand Names
- Xalkori
- Generic Name
- Crizotinib
- DrugBank Accession Number
- DB08865
- Background
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Crizotinib (DB08865)
- Weight
- Average: 450.337
Monoisotopic: 449.11854397 - Chemical Formula
- C21H22Cl2FN5O
- Synonyms
- (R)-crizotinib
- Crizotinib
- Crizotinibum
- External IDs
- 1066
- PF 02341066
- PF 2341066
- PF-02341066
- PF-2341066
Pharmacology
- Indication
Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.
Target Actions Organism AALK tyrosine kinase receptor inhibitorHumans AHepatocyte growth factor receptor inhibitorHumans - Absorption
The peak serum concentration was reached in 4 to 6 hours following an oral single-dose administration. Steady state was reached within 15 days when a dose of 250 mg twice daily was administered. The mean absolute bioavailability was 43% (range of 32% to 66%) following a single 250 mg oral dose. When taken with high-fat meal, AUC and Cmax were reduced.
- Volume of distribution
Mean volume of distribution (Vss) is 1772 L following intravenous administration of a 50 mg dose. This high volume of distribution suggest extensive distribution into tissue from plasma.
- Protein binding
Crizotinib is 91% bound to plasma protein. This is not affected by drug concentration.
- Metabolism
Crizotinib is metabolized by CYP3A4 and CYP3A5 in which these enzymes mediates the O-dealkylation of the drug.
- Route of elimination
Following the administration of a single 250 mg radiolabeled crizotinib dose to healthy subjects, 63% and 22% of the administered dose was recovered in feces and urine, respectively. Unchanged crizotinib represented approximately 53% and 2.3% of the administered dose in feces and urine, respectively.
- Half-life
Plasma terminal half-life, patients = 42 hours
- Clearance
The mean apparent clearance (CL/F) of crizotinib was lower at steady state (60 L/hr) after 250 mg twice daily than that after a single 250 mg oral dose (100 L/hr), which was likely due to autoinhibition of CYP3A by crizotinib after multiple dosing.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be decreased when combined with Crizotinib. Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Crizotinib. Abametapir The serum concentration of Crizotinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Crizotinib can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Crizotinib. Abiraterone The metabolism of Abiraterone can be decreased when combined with Crizotinib. Abrocitinib The serum concentration of Crizotinib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Crizotinib. Acebutolol Acebutolol may increase the bradycardic activities of Crizotinib. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Crizotinib. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of crizotinib.
- Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of crizotinib.
- Take with or without food. High-fat food decreases drug absorption, but not to a clinically significant extent.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Xalkori Capsule 250 mg Oral Pfizer Europe Ma Eeig 2016-09-08 Not applicable EU 
Xalkori Capsule 200 mg Oral Pfizer Europe Ma Eeig 2016-09-08 Not applicable EU Xalkori Capsule 200 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 2011-08-26 Not applicable US 
Xalkori Capsule 250 mg Oral Pfizer Europe Ma Eeig 2016-09-08 Not applicable EU Xalkori Capsule 250 mg Oral Pfizer Canada Ulc 2012-05-10 Not applicable Canada 
Xalkori Capsule 250 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 2011-08-26 Not applicable US Xalkori Capsule 200 mg Oral Pfizer Europe Ma Eeig 2016-09-08 Not applicable EU Xalkori Capsule 200 mg Oral Pfizer Canada Ulc 2012-05-10 Not applicable Canada
Categories
- ATC Codes
- L01XE16 — Crizotinib
- Drug Categories
- Aminopyridines
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- Bradycardia-Causing Agents
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (moderate)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Enzyme Inhibitors
- Kinase Inhibitor
- Moderate Risk QTc-Prolonging Agents
- Narrow Therapeutic Index Drugs
- OCT2 Inhibitors
- Organic Cation Transporter 1 Inhibitors
- P-glycoprotein inhibitors
- P-glycoprotein substrates
- P-glycoprotein substrates with a Narrow Therapeutic Index
- Piperidines
- Protein Kinase Inhibitors
- Pyridines
- QTc Prolonging Agents
- Receptor Tyrosine Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrazolylpyridines. These are compounds containing a pyrazolylpyridine skeleton, which consists of a pyrazole linked (not fused) to a pyridine by a bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyrazolylpyridines
- Direct Parent
- Pyrazolylpyridines
- Alternative Parents
- Dichlorobenzenes / Alkyl aryl ethers / Aminopyridines and derivatives / Fluorobenzenes / Piperidines / Aryl chlorides / Aryl fluorides / Imidolactams / Pyrazoles / Heteroaromatic compounds show 7 more
- Substituents
- 1,3-dichlorobenzene / 3-pyrazolylpyridine / Alkyl aryl ether / Amine / Aminopyridine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine (CHEBI:64310)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 53AH36668S
- CAS number
- 877399-52-5
- InChI Key
- KTEIFNKAUNYNJU-GFCCVEGCSA-N
- InChI
- InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
- IUPAC Name
- 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
- SMILES
- C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
References
- General References
- Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [Article]
- Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [Article]
- External Links
- KEGG Drug
- D09731
- PubChem Compound
- 11626560
- PubChem Substance
- 310264901
- ChemSpider
- 9801307
- BindingDB
- 50306682
- 1148495
- ChEBI
- 64310
- ChEMBL
- CHEMBL601719
- ZINC
- ZINC000035902489
- PharmGKB
- PA165946122
- PDBe Ligand
- VGH
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Crizotinib
- PDB Entries
- 2wgj / 2xp2 / 2yfx
- FDA label
- Download (279 KB)
- MSDS
- Download (105 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment ALK or ROS1-positive NSCLC 1 4 Recruiting Treatment ALCL / IMT / Non-Small Cell Lung Carcinoma (NSCLC) 1 4 Recruiting Treatment Anaplastic Large Cell Lymphoma, ALK-Positive 1 4 Withdrawn Treatment Systemic Anaplastic Large Cell Lymphoma 1 3 Active Not Recruiting Treatment Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 3 Active Not Recruiting Treatment Neoplastic Disease 1 3 Active Not Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 3 3 Completed Treatment Advanced Malignancies / Carcinoma / Lung Cancers / Non-Small Cell Lung Carcinoma (NSCLC) 1 3 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 2 3 Not Yet Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Capsule Oral 200 mg/1 Capsule Oral 250 mg/1 Capsule, coated Oral 200 mg Capsule, coated Oral 250 mg Capsule Oral 200 mg Capsule Oral 250 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2517256 No 2013-04-30 2024-02-26 Canada CA2577937 No 2010-12-21 2025-08-15 Canada CA2578066 No 2011-10-11 2025-08-15 Canada CA2632286 No 2011-11-15 2026-11-23 Canada US7825137 No 2010-11-02 2027-05-12 US US7858643 No 2010-12-28 2029-10-08 US US7230098 No 2007-06-12 2025-08-26 US US8217057 No 2012-07-10 2029-11-06 US US8785632 No 2014-07-22 2025-03-01 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 1.83 MSDS - Predicted Properties
Property Value Source Water Solubility 0.00611 mg/mL ALOGPS logP 3.82 ALOGPS logP 3.57 ChemAxon logS -4.9 ALOGPS pKa (Strongest Basic) 10.12 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 77.99 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 128.43 m3·mol-1 ChemAxon Polarizability 45.44 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9721 Caco-2 permeable - 0.5672 P-glycoprotein substrate Substrate 0.6938 P-glycoprotein inhibitor I Non-inhibitor 0.6713 P-glycoprotein inhibitor II Inhibitor 0.7105 Renal organic cation transporter Inhibitor 0.5464 CYP450 2C9 substrate Non-substrate 0.7545 CYP450 2D6 substrate Non-substrate 0.7023 CYP450 3A4 substrate Substrate 0.6029 CYP450 1A2 substrate Inhibitor 0.6676 CYP450 2C9 inhibitor Inhibitor 0.5 CYP450 2D6 inhibitor Non-inhibitor 0.8662 CYP450 2C19 inhibitor Inhibitor 0.6237 CYP450 3A4 inhibitor Non-inhibitor 0.6301 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8676 Ames test Non AMES toxic 0.5981 Carcinogenicity Non-carcinogens 0.8018 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6581 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.643 hERG inhibition (predictor II) Inhibitor 0.7877
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0udi-1693800000-fc52c38f3359a378554a
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transmembrane receptor protein tyrosine kinase activity
- Specific Function
- Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis a...
- Gene Name
- ALK
- Uniprot ID
- Q9UM73
- Uniprot Name
- ALK tyrosine kinase receptor
- Molecular Weight
- 176440.535 Da
References
- Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Protein tyrosine kinase activity
- Specific Function
- Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including...
- Gene Name
- MET
- Uniprot ID
- P08581
- Uniprot Name
- Hepatocyte growth factor receptor
- Molecular Weight
- 155540.035 Da
References
- Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Components:
| Name | UniProt ID |
|---|---|
| Cytochrome P450 3A4 | P08684 |
| Cytochrome P450 3A43 | Q9HB55 |
| Cytochrome P450 3A5 | P20815 |
| Cytochrome P450 3A7 | P24462 |
References
- Filppula AM, Neuvonen PJ, Backman JT: In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9. doi: 10.1124/dmd.114.057695. Epub 2014 Apr 8. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [Article]
Drug created at March 28, 2013 17:22 / Updated at July 02, 2022 14:09